ARNI在高血压治疗中的研究进展

doi:10.3969/j.issn.1004-583X.2023.02.015

摘要/Abstract

摘要：

高血压是常见的慢性疾病之一,通常会导致心、脑、肾等靶器官的功能及器质性损害,正是由于高血压与心肾脑疾病之间的相互关系,促使高血压的管理从单纯的降压治疗转变为心、肾、脑等疾病的全程保护,而相关研究指出血管紧张素受体脑啡肽酶抑制剂具有此保护作用,其代表药物为沙库巴曲缬沙坦。2021年《沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议》指出:沙库巴曲缬沙坦是新一类的降压药物,具备双靶点效应,此药物在增强利钠肽系统活性的同时抑制肾素血管紧张素醛固酮系统活性,降压作用显著,并具有靶器官保护作用。本文旨在对沙库巴曲缬沙坦片对高血压治疗的疗效及研究进展进行阐述。

关键词: 高血压, 抗高血压药, 血管紧张素受体脑啡肽酶抑制剂, 心钠素

中图分类号:

R544.1

郭雨, 李永东. ARNI在高血压治疗中的研究进展[J]. 临床荟萃, 2023, 38(2): 181-184.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2023.02.015

https://huicui.hebmu.edu.cn/CN/Y2023/V38/I2/181

参考文献 21

[1]	Yin R, Yin L, Li L, et al. Hypertension in China: Burdens, guidelines and policy responses: A state-of-the-art review[J]. J Hum Hypertens, 2022, 36(2):126-134. doi: 10.1038/s41371-021-00570-z
[2]	中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2):108-114.
[3]	Unger T, Borghi C, Charchar F, et al. 2020 international society of hypertension global hypertension practice guidelines[J]. J Hypertens, 2020, 38(6):982-1004. doi: 10.1097/HJH.0000000000002453 pmid: 32371787
[4]	Miceli F, Presta V, Citoni B, et al. Conventional and new electrocardiographic criteria for hypertension-mediated cardiac organ damage: A narrative review[J]. J Clin Hypertens (Greenwich), 2019, 21(12):1863-1871. doi: 10.1111/jch.13726 pmid: 31693279
[5]	Konukoglu D, Uzun H. Endothelial dysfunction and hypertension[J]. J Adv Exp Med Biol, 2017, 956:511-540.
[6]	Gkaliagkousi E, Gavriilaki E, Triantafyllou A, et al. Clinical significance of endothelial dysfunction in essential hypertension[J]. J Curr Hypertens Rep, 2015, 17(11):85.
[7]	Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression [published correction appears in J Vet Intern Med. 2019 Sep;33(5):2551][J]. J Vet Intern Med, 2019, 33(2):363-382. doi: 10.1111/jvim.15454 pmid: 30806496
[8]	Mattson DL. Immune mechanisms of salt-sensitive hypertension and renal end-organ damage[J]. J Nat Rev Nephrol, 2019, 15(5):290-300.
[9]	Cheung CY, Tay WT, Mitchell P, et al. Quantitative and qualitative retinal microvascular characteristics and blood pressure[J]. J Hypertens, 2011, 29(7):1380-1391. doi: 10.1097/HJH.0b013e328347266c pmid: 21558958
[10]	Dziedziak J, Zaleska-Żmijewska A, Szaflik JP, et al. Impact of arterial hypertension on the eye: A review of the pathogenesis, diagnostic methods, and treatment of hypertensive retinopathy[J]. J Med Sci Monit, 2022, 28:e935135.
[11]	McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004. doi: 10.1056/NEJMoa1409077 URL
[12]	Kuwahara K. The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications[J]. J Pharmacol Ther, 2021, 227:107863. doi: 10.1016/j.pharmthera.2021.107863 URL
[13]	Corvol P. Le système rénine-angiotensine-aldostérone et son inhibition [The renin-angiotensin-aldosterone system and its suppression][J]. J Ann Pediatr (Paris), 1982, 29(9):657-658.
[14]	Kjeldsen SE, Narkiewicz K, Burnier M, et al. Will we ever use angiotensin receptor neprilysin inhibition (ARNi) for the treatment of hypertension?[J]. BloodPress, 2019, 28(2):75-76.
[15]	Yamamoto K, Rakugi H. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment[J]. J Hypertens Res, 2021, 44(10):1239-1250.
[16]	Myhre PL, Prescott MF, Murphy SP, et al. Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril/valsartan: A pooled analysis of EVALUATE-HF and PROVE-HF[J]. J JACC Heart Fail, 2022, 10(2):119-128.
[17]	Huo Y, Li W, Webb R, et al. Efficacy and safety of sacubitril/valsartan compared with olmesartan in Asian patients with essential hypertension: A randomized, double-blind, 8-week study[J]. J Clin Hypertens (Greenwich), 2019, 21(1):67-76. doi: 10.1111/jch.13437 pmid: 30536595
[18]	Writing Committee Members, Gulati M, Levy PD, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: A report of the American college of Cardiology/American heart association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol, 2021, 78(22):e187-e285. doi: 10.1016/j.jacc.2021.07.053 URL
[19]	Williams B, Cockcroft JR, Kario K, et al. Effects of Sacubitril/Valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: The PARAMETER study[J]. J Hypertension, 2017, 69(3):411-420.
[20]	Kario K, Tamaki Y, Okino N, et al. LCZ696, a First-in-Class angiotensin Receptor-Neprilysin inhibitor: The first clinical experience in patients with severe hypertension[J]. J Clin Hypertens (Greenwich), 2016, 18(4):308-314. doi: 10.1111/jch.12667 pmid: 26402918
[21]	Writing Committee Members, ACC/AHA Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the management of heart failure[J]. J Card Fail, 2022, 28(5):e1-e167. doi: 10.1016/j.cardfail.2022.02.010 pmid: 35378257

ARNI在高血压治疗中的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李志勇, 李星. 多模态超声在高血压患者大脑中动脉狭窄筛查中的临床价值[J]. 临床荟萃, 2023, 38(7): 613-617.
[2]	刘奕, 崔坤, 刘畅, 赵浩天, 李丽, 薛红元. 血清分泌型卷曲蛋白5水平与原发性高血压患者早期肾损害的相关性[J]. 临床荟萃, 2023, 38(12): 1073-1077.
[3]	江吉, 朱小刚, 姜山, 达哇扎巴, 岑强. 世居高原高血压人群蛋白尿相关危险因素[J]. 临床荟萃, 2023, 38(12): 1086-1090.
[4]	杨晓蓉, 周淑红, 潘亮, 郭莉江. 结缔组织病相关肺动脉高压的发病机制及其筛查的研究进展[J]. 临床荟萃, 2023, 38(10): 944-948.
[5]	徐阳, 薛凌. H型高血压合并2型糖尿病患者轻度认知功能障碍的影响因素[J]. 临床荟萃, 2023, 38(10): 887-892.
[6]	李瑞珍, 李星辉, 曾璟, 姚晓涛, 杨珂欣, 张展. 高血压认知功能障碍机制的研究进展[J]. 临床荟萃, 2023, 38(1): 88-92.
[7]	王宁, 李勇. 簇集蛋白在心血管疾病中的研究进展[J]. 临床荟萃, 2022, 37(9): 842-845.
[8]	尹贻锟, 尹逊伟, 王佳林, 孙君志. 太极拳锻炼周期对原发性高血压的血压及心血管危险因素的影响:系统性评价和Meta分析[J]. 临床荟萃, 2022, 37(7): 599-606.
[9]	邱建美, 王德峰. 恩格列净治疗2型糖尿病的研究现状[J]. 临床荟萃, 2022, 37(2): 170-173.
[10]	刘慧, 姚卫杰, 赵辉. 高血压致射血分数保留心力衰竭的发病机制及治疗措施探讨[J]. 临床荟萃, 2021, 36(9): 839-842.
[11]	叶蒙蒙, 李旎, 徐国栋, 邵国丰. miR-361在心血管疾病的研究进展[J]. 临床荟萃, 2021, 36(9): 843-849.
[12]	王亚柱, 郭云飞, 司月乔, 刘超, 张英. 心外膜脂肪组织体积与原发性高血压合并冠心病的相关性[J]. 临床荟萃, 2021, 36(8): 699-703.
[13]	李志勇, 李星, 何真. 肾动脉小慢波频谱联合超声心动图对成人型主动脉缩窄的临床价值[J]. 临床荟萃, 2021, 36(8): 739-743.
[14]	刘阔, 崔炜. 高血压诊疗基础问题再探讨:血压测量、降压目标、降压策略[J]. 临床荟萃, 2021, 36(8): 744-748.
[15]	巩涛, 胡月圆, 高云, 郭畅, 沈慧楠, 王东玉. H型高血压与LAA型急性脑梗死早期神经功能缺损严重程度的关系[J]. 临床荟萃, 2021, 36(7): 612-615.